Valuation: RemeGen Co., Ltd.

Capitalization 58.73B 67.72B 8.65B 7.39B 6.77B 6.4B 11.85B 828B 11.91B 80.58B 31.37B 393B 32.45B 31.77B 1,365B P/E ratio 2026 *
12.5x
P/E ratio 2027 * 60.9x
Enterprise value 55.79B 64.33B 8.22B 7.02B 6.43B 6.08B 11.25B 786B 11.31B 76.55B 29.8B 373B 30.83B 30.18B 1,297B EV / Sales 2026 *
7.72x
EV / Sales 2027 * 12x
Free-Float
55.89%
Yield 2026 *
-
Yield 2027 * -
1 day-2.53%
1 week-5.32%
Current month-8.05%
1 month-15.83%
3 months+15.19%
6 months+9.47%
Current year+28.47%
1 week 90.25
Extreme 90.25
101.7
1 month 90.25
Extreme 90.25
123.1
Current year 69.7
Extreme 69.7
123.1
1 year 39.25
Extreme 39.25
126.6
3 years 10.2
Extreme 10.2
126.6
5 years 10.2
Extreme 10.2
145.5
10 years 10.2
Extreme 10.2
149.8
Manager TitleAgeSince
Chief Executive Officer 64 04/07/2008
Director of Finance/CFO 55 28/09/2023
Corporate Secretary 60 11/05/2020
Director TitleAgeSince
Director/Board Member 64 04/07/2008
Director/Board Member 71 04/07/2008
Director/Board Member 56 11/05/2020
Change 5d. change 1-year change 3-years change Capi.($)
-2.53%-5.32%+135.97%+134.47% 8.84B
-1.58%-0.17%+40.62%+85.63% 50.91B
-1.28%-0.07%+81.96%+64.48% 49.21B
-1.53%-3.18%-2.40%-12.36% 23.69B
+1.72%-13.93%+79.56%+529.95% 25.14B
+0.47%+2.67%+46.26%-26.47% 17.81B
-1.66%-4.83%+32.60%-41.30% 16.5B
-2.08%-4.64%+57.35%+199.18% 15.3B
-0.84%+5.27%-23.65%+992.44% 14.71B
-1.82%-1.57%+43.62% - 13.73B
Average -1.11%-1.44%+49.19%+214.00% 23.58B
Weighted average by Cap. -1.05%-1.88%+49.77%+172.19%

Financials

2026 *2027 *
Net sales 7.22B 8.33B 1.06B 908M 832M 787M 1.46B 102B 1.46B 9.91B 3.86B 48.3B 3.99B 3.91B 168B 4.63B 5.34B 682M 583M 534M 505M 934M 65.29B 939M 6.36B 2.47B 30.98B 2.56B 2.51B 108B
Net income 3.6B 4.15B 530M 453M 415M 392M 726M 50.73B 730M 4.94B 1.92B 24.07B 1.99B 1.95B 83.68B 743M 857M 109M 93.44M 85.62M 80.94M 150M 10.47B 151M 1.02B 397M 4.97B 411M 402M 17.27B
Net Debt -2.94B -3.39B -433M -370M -339M -320M -593M -41.43B -596M -4.03B -1.57B -19.66B -1.62B -1.59B -68.34B -3.03B -3.5B -446M -381M -349M -330M -612M -42.73B -615M -4.16B -1.62B -20.28B -1.68B -1.64B -70.47B
Logo RemeGen Co., Ltd.
RemeGen Co Ltd is a China-based company primarily engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company’s main business is engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and other products. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company conducts its business in the domestic and overseas markets.
Employees
3,048
Date Price Change Volume
13/05/26 92.50 $ -2.53% 3,276,550
12/05/26 94.90 $ -3.51% 3,895,415
11/05/26 98.35 $ +0.67% 4,026,000
08/05/26 97.70 $ -3.74% 2,487,975
07/05/26 101.50 $ +3.89% 3,083,826
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
80.22CNY
Average target price
96.82CNY
Spread / Average Target
+20.70%

Quarterly revenue - Rate of surprise